Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Boosting Resources for Tracheostomy Care at Home Enrollment reduced: 480 → 330 participants Massachusetts General HospitalNot applicable NCT06283953
  2. Notable: Correlation of Pelvic Sentinel Lymph Node With Superficial Vein Enrollment reduced: 100 → 50 participants Istanbul UniversityNot applicable NCT06741007
  3. Notable: Baropodometric Patterns Associated With Metatarsalgia Enrollment reduced: 180 → 120 participants University of SevilleNot applicable NCT06534073
  4. Notable: Prevelance of Uterine Vein and Uterine Vein System Variations Enrollment reduced: 100 → 50 participants Istanbul UniversityNot applicable NCT06520969
  5. Notable: Natural History Study of POLG Disease Enrollment reduced: 300 → 200 participants The POLG FoundationNot specified NCT07775872
  6. Notable: CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) Recruitment opened Caliway Biopharmaceuticals Co., Ltd.Phase 3 NCT07526974
  7. Notable: Povetacicept · Primary Membranous Nephropathy (pMN) Primary and study completion pushed from Dec 29, 2028 to Jun 27, 2029 Vertex Pharmaceuticals IncorporatedPhase 2/3 NCT07204275
  8. Notable: Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, · Extensive-Stage Small Cell Lung Cancer Primary endpoint(s) modified PfizerPhase 2/3 NCT07226999
  9. Notable: Silevertinib (BDTX-1535) · Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Primary completion pushed from Nov 3, 2025 to Mar 2028 Black Diamond Therapeutics, Inc.Phase 1/2 NCT05256290
  10. Notable: ICP-B381 · Advanced Solid Tumors Recruitment opened Beijing InnoCare Pharma Tech Co., Ltd.Phase 1/2 NCT07901413
  11. Notable: CRMA-1001 · Chronic Hepatitis B Primary and study completion moved earlier from Dec 31, 2032 to Feb 2031 nChroma BioPhase 1/2 NCT07200193
  12. Notable: VIB305 · Advanced Solid Tumors Primary endpoint(s) modified Vibrant Sciences LimitedPhase 1/2 NCT07222969
  13. Notable: Automated Versus Manual Oxygen Titration With the EMILY.AI Device · Acute Respiratory Failure Primary endpoint(s) modified Aether Tech S.L.Not applicable NCT07932847
  14. Notable: Quantitative Refractive Crosslinking in Adults and Presbyopia-Aged Patients in the Philippines Primary completion pushed from Aug 2026 to May 2027 TECLens, Inc.Not applicable NCT07208604
  15. Notable: Coverage With Evidence Development Study of Percutaneous Image-Guided Lumbar Decompression (PILD) With the Freedom DS Instrument System (FREEDOM-CED) Primary endpoint(s) modified Spinal Simplicity LLCNot specified NCT07938853
  16. Notable: Quantitative Refractive Crosslinking in Adults and Presbyopia-Aged Patients Primary completion pushed from Aug 2026 to May 2027 TECLens, Inc.Not applicable NCT07137767
  17. Notable: Relationship Between Body Mass Index Percentiles and Radial and Ulnar Artery Diameters in Pediatric Patients Primary endpoint(s) modified Ankara Etlik City HospitalNot specified NCT07926139
  18. Notable: Oral Iron · Chronic Kidney Disease Results posted: Nov 18, 2026 Weill Medical College of Cornell UniversityPhase 4 NCT03991169
  19. Notable: Esketamine Versus Sufentanil for Sedation in Patients Undergoing ERCP Phase changed: Not applicable → Phase 4 Ren DaPhase 4 NCT07702240
  20. Notable: Spinal Mobilization Added to Exercise Therapy for Chronic Non-Specific Low Back Pain Enrollment increased: 30 → 60 participants Biruni UniversityNot applicable NCT07749898
  21. Notable: Outcomes of Continuous Positive Airway Pressure Treatment · Obstructive Sleep Apnea and Chronic Pain Primary completion pushed from Dec 2025 to Apr 2027 Vrije Universiteit BrusselNot specified NCT06834724
  22. Notable: Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device Primary endpoint(s) modified Chinese University of Hong KongNot applicable NCT06295497
  23. Notable: SCLC Blood Collection Study Enrollment increased: 25 → 100 participants Duke UniversityNot specified NCT07468656
  24. Notable: Pasteurized Akkermansia Massiliensis LWHK0003 Supplementation · MASLD Primary endpoint(s) modified National Taiwan University HospitalNot applicable NCT06873165
  25. Notable: Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance Primary endpoint(s) modified Ottawa Heart Institute Research CorporationNot applicable NCT03536312